Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

NCT03527147 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

NHL
DLBCL
Non-hodgkin's Lymphoma
Diffuse Large B Cell Lymphoma

Interventions

DRUG: AZD9150
DRUG: Acalabrutinib
DRUG: AZD6738
DRUG: Hu5F9-G4
DRUG: Rituximab
DRUG: AZD5153

Sponsor

Acerta Pharma BV

Collaborators

[object Object]